Will intracytoplasmic morphologically selected sperm injection replace intracytoplasmic sperm injection in cases of severe oligo-astheno-teratozoospermia ? A prospective study comparing pregnancy outcome

Completed

• Conditions: male factor infertility and IMSI; Reproductive Health and Childbirth - Fertility including in vitro fertilisation

• Registration Number: ACTRN12615000668505
• Lead Sponsor: alexandria university, faculty of medicne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-06-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1729

Inclusion Criteria

very poor semen quality characterized by severe oligo-astheno-teratozoospermia (sperm concentration less than 5 million per ml, less than 50% motile sperms according to WHO criteria and less than 14% morphologically normal spermatozoa according to the Strict Kruger Criteria), a normal karyotype in both partners
.

Exclusion Criteria

Uterine defects, hydrosalpinx, endometriosis, polycystic ovaries, evidence of low ovarian response in previous treatment cycles (less than four oocytes retrieved), infections, endocrinal problems, coagulation defects or thrombophilia and autoimmune defects (including antiphospholipid antibodies) were all excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measure is the pregnancy rate which is diagnosed by positive serum beta-hCG assay (> 50 IU/L) 14 days after embryo transfer (ET) . Moreover, clinical pregnancy is confirmed by observing the number of the gestational sacs and fetal cardiac pulsations 2 weeks after positive beta -hCG test by trans-vaginal ultrasonography (TVS).<br>[one year]

Secondary Outcome Measures

Name	Time	Method
embryo grade by microscopy[5days];Fertilization rate[One month]